Engineering Guide · Vendor-Neutral

tac Promoter vs T7 Promoter: E. coli Expression Decision Guide

Published June 2, 2026 · 11 min read
tac promoter (host RNA polymerase) vs T7 promoter (T7 RNA polymerase) side-by-side tac PROMOTER hybrid trp(-35) / lacUV5(-10) -35 -10 RNAP gene of interest Any K-12 / B host ~5x lacUV5 strength IPTG-tunable, slower folding-friendly rate VS T7 PROMOTER phage promoter, T7 RNAP T7 T7P gene of interest BL21(DE3) only ~5x host RNAP speed very high titer, prone to inclusion bodies Both systems: IPTG induction · lacI/lacIq repression · same cost per batch
Figure 1: tac is a hybrid trp/lac promoter read by E. coli RNA polymerase; T7 is a phage promoter that requires T7 RNA polymerase (supplied by the DE3 lysogen in BL21(DE3)). Both induced by IPTG.
Quick Verdict

Pick T7 for maximum titer of soluble, well-behaved cytoplasmic proteins in BL21(DE3). Pick tac when the target is toxic, membrane-bound, disulfide-rich, or aggregates as inclusion bodies. T7 wins on raw transcription rate (~5x host RNAP); tac wins on tight repression, slower translation that favours folding, and the freedom to run in any E. coli host.

Key differences at a glance

Side-by-side comparison

Factor tac promoter T7 promoter
Transcription machinery E. coli RNA polymerase Bacteriophage T7 RNA polymerase
Relative strength ~5x lacUV5; ~3x trp ~5x E. coli RNAP rate
Host strain requirement Any K-12 or B (BL21, JM109, MG1655, Origami, Rosetta) BL21(DE3) or other DE3 lysogen only
Basal leakiness Moderate; rises in long culture Low with T7lac + pLysS; high without
Inducer IPTG (0.025-1.0 mM) IPTG (0.025-0.5 mM typical)
Tunability Smooth dose response over ~3 orders of magnitude Steeper response; saturates ribosomes fast
Toxic protein tolerance Better; slower transcription buys folding time Weak; needs pLysS or T7lac to control
Soluble fraction Often higher (slower translation) Lower; inclusion bodies common at 37 degrees C
Typical max titer (well-behaved target) 10-50 mg/L (lab scale) Up to 30% of total cellular protein

Values are typical literature ranges. Actual performance depends on plasmid backbone, copy number, codon usage, growth conditions, and the target protein itself.

tac promoter in detail

The tac promoter was constructed in 1983 by Amann, Brosius and Ptashne as a deliberate fusion of the -35 hexamer from the trp promoter and the -10 hexamer (plus the operator) from the lacUV5 promoter. The hybrid takes the strongest known E. coli RNAP recognition elements and stitches them together with a 16 bp spacer, producing a promoter that the host polymerase reads roughly five times more efficiently than lacUV5 alone and roughly three times more than the parental trp promoter. Because it is read by host RNAP, tac works in any E. coli strain that carries lacI (for repression). Vectors most often used today are the pKK and pMAL series from Sigma/NEB and the pGEX glutathione-S-transferase fusion family from Cytiva.

How it works

tac is repressed in the uninduced state by LacI binding the lac operator that sits inside the -10 region. In strains carrying the lacIq allele (which overproduces LacI ~10-fold compared with wild-type), repression efficiency is roughly 50-fold. Adding IPTG dissociates LacI, freeing the promoter for E. coli RNA polymerase. Because the polymerase is the same one that transcribes the host genome, transcription rate of the target gene scales with the cellular RNAP pool. That pool is finite, so tac cannot indefinitely outrun host gene expression. That ceiling is what makes tac well-behaved: it cannot drain the transcription/translation machinery to the point of collapse the way an unleashed T7 RNAP can.

When tac wins

tac wins in five common situations: (1) toxic proteins where slower transcription gives the cell time to dilute the product as it grows; (2) membrane proteins, where Sec translocon throughput is limited and a fire-hose-strength T7 promoter often saturates the membrane and triggers BL21 cell death; (3) disulfide-rich or eukaryotic proteins needing host backgrounds without (DE3) (Origami for trxB/gor mutations, Rosetta-gami for tRNA + disulfide combined); (4) tunable expression studies where you want to titrate IPTG across orders of magnitude to find the soluble-yield sweet spot; (5) any project where inclusion bodies have been the bottleneck. A 2021 Frontiers in Microbiology study showed that pSF-p15A-trc (low copy backbone, tac/trc-class promoter) gave 53 mg/L of YFP, three times higher than the same target on a T7lac backbone, because the slower transcription rate matched ribosome availability better.

T7 promoter in detail

The T7 expression system was developed by Studier and Moffatt in the mid-1980s and remains the most widely used heterologous expression platform in research labs. It rests on two pieces: the T7 promoter on the expression plasmid (the pET series from Novagen / Merck dominates this space) and a chromosomally integrated copy of T7 RNA polymerase under lacUV5 control in the BL21(DE3) host. T7 RNA polymerase reads its phage promoter exclusively (host RNAP cannot) and transcribes at roughly five times the rate of E. coli RNAP. That speed is the whole story: when the T7 RNAP is uncaged with IPTG it commandeers a large fraction of the ribosome pool, producing recombinant protein at levels that can reach 30% of total cellular protein for cooperative targets.

How it works

IPTG induces the lacUV5 promoter on the DE3 lysogen, derepressing the gene encoding T7 RNA polymerase. The newly translated T7 RNAP then reads its phage promoter on the pET plasmid and transcribes the cloned gene. Modern pET vectors carry the T7lac variant of the promoter, which adds a lac operator downstream of the T7 -17 to +6 region. T7lac requires LacI to release the operator (additional IPTG control), giving better basal repression than plain T7. For proteins where even T7lac leaks too much, BL21(DE3) pLysS from NEB adds constitutive T7 lysozyme expression, which binds and inhibits any T7 RNAP that escapes lac repression. pLysE (higher T7 lysozyme) further tightens the leash for extremely toxic targets.

When T7 wins

T7 wins whenever the target is (1) cytoplasmic and well-behaved, (2) biophysically robust enough to refold from inclusion bodies if you decide to embrace solubilisation, or (3) scale-dependent. At 100-1000 L industrial fermentation, the raw volumetric productivity from T7lac/BL21(DE3) is hard to beat for soluble enzymes, antibody Fab fragments, and structural genomics targets. Many commercial recombinant protein platforms (including Thermo Fisher Champion pET, Lucigen Expresso, and the original Novagen pET system that became MilliporeSigma's flagship) are built around T7. The Lonza XS Microbial Expression Technologies platform similarly defaults to T7 for cytoplasmic targets and switches to alternatives only when the protein argues for it.

Pros and cons

tac promoter

Advantages

  • Works in any E. coli strain (no (DE3) lysogen required), enabling Origami, Rosetta-gami, K-12 hosts
  • Smooth IPTG dose-response over ~3 orders of magnitude. Easy to titrate for soluble yield
  • Slower transcription gives better folding time and a higher soluble fraction for difficult targets
  • Lower metabolic burden on the host. Better growth phenotype at high cell density

Disadvantages

  • Lower peak titer than T7 for well-behaved cytoplasmic targets
  • Moderate basal expression. Toxic proteins still need a lacIq host or chromosomally integrated LacI
  • Fewer modern vector options. Most commercial platforms default to T7
  • Older literature can be inconsistent: trc vs tac vs tic vs trc99A. Same family, different vendors

T7 promoter

Advantages

  • Highest raw expression of any common bacterial system. Up to 30% of total cellular protein
  • Huge plasmid ecosystem (pET family, pTriEx, pCold T7) and supported by all major vendors
  • Fast induction kinetics. Protein detectable in minutes, peak at 3-5 h
  • Predictable behaviour in industrial fermentation. Well-characterised at 1000 L scale

Disadvantages

  • Restricted to (DE3) hosts. Cannot run in Origami, Rosetta, K-12 without retrofitting T7 RNAP
  • Leakiness from the lacUV5 driver in DE3 can kill cultures expressing toxic proteins
  • Common inclusion body problem. Fast transcription outruns folding chaperones
  • Metabolic mismatch with high copy plasmids. Pairing pET on pUC origin with strong induction often reduces yield

Which should you choose?

The choice usually collapses to one of four scenarios. Identify yours, follow the recommendation, and reassess after the first round of solubility screening.

Maximum titer, soluble cytoplasmic target

You need raw volumetric productivity. The protein is well-folded, not toxic, no disulfides. Typical structural genomics, enzyme production, or commodity research-grade protein.

Choose T7 + BL21(DE3)

Toxic, membrane, or disulfide-rich protein

The target kills cells when leaked, requires Sec or signal peptide translocation, or needs oxidising cytoplasm (Origami trxB/gor) for proper disulfides.

Choose tac (or trc)

Inclusion bodies dominate at T7 baseline

The protein expresses at high level but ends up insoluble. You have already tried lower temperature and lower IPTG with T7. Switching to a slower promoter and any host is the next lever.

Switch to tac at 18-25 C

Tunable / inducible system for studies

You need expression level as a controlled variable. Dose-response titrations, gene regulation studies, or staged metabolic engineering knock-ins.

Choose tac on a low-copy plasmid

Real-world use cases

Patterns from published process descriptions and lab-to-pilot scale-ups.

Industrial enzyme, 1000 L
T7 / pET / BL21(DE3)

Lonza, Boehringer, and contract microbial CMOs default to pET-derived T7 vectors for soluble industrial enzymes. Run length 24-36 h, IPTG 0.1-0.5 mM, induction OD600 of 30-50 in fed-batch. Titer envelope 2-8 g/L.

Membrane protein, 1 L
tac / pBAD / Lemo21(DE3)

Structural biology and GPCR groups overwhelmingly use tunable systems for membrane targets. tac on low-copy plasmids or pBAD arabinose induction. The folding/insertion machinery is rate-limiting; raw transcription strength hurts.

Antibody Fab fragment
T7 + pelB signal / BL21(DE3)

Single-chain Fv and Fab production for biopharma discovery typically uses pET-based T7 with a pelB or DsbA leader for periplasmic export. T7 speed is fine here because the bottleneck is downstream (DsbA/DsbC oxidative folding), not transcription.

Toxic / fluorescent reporter
tac / lacIq / JM109 or BL21(DE3) pLysS

RFP variants, antimicrobial peptides, restriction enzymes, ribosome-disrupting toxins. Anything where leakage kills the host. tac in a lacIq background gives ~50-fold repression; if T7 is forced, pLysS or pLysE is mandatory.

Need to plan IPTG induction for either promoter?

The E. coli Expression Optimizer scores your construct against host strain, induction OD, temperature, and IPTG dose, and returns a tuned condition matrix for both T7 and tac/trc plasmids.

Open the E. coli Expression Optimizer

Cost and lifecycle considerations

Cost of tac vs T7 is essentially identical

Both systems use IPTG, both run in BL21 derivatives, and both share the same fermentation media, vessel geometry, and downstream capture. The economic difference is not in capex or opex but in yield per batch, and yield depends on the target, not the promoter. Pick the promoter that gives your specific target the best soluble fraction, then optimise.

Per-litre fermentation cost is dominated by media, energy, and harvest. The promoter contributes nothing material to either. Licensing is a small consideration. The pET/T7 promoter is widely available through Novagen / MilliporeSigma with the standard biological license; pTrc/pKK/pMAL are similarly distributed. The pET license restricts commercial use without a separate agreement, which is why some industrial groups still build new platforms around tac/trc to keep the licensing path simpler.

The real cost driver between the two is development time. If you have a portfolio of well-behaved targets, T7 reaches first-titer-data fastest. If your target needs solubility screening (most enzymes do, every membrane protein does), the second-round switch from T7 to tac costs you weeks of cloning. Many groups now keep parallel pET (T7) and pTrc (tac) versions of every gene from day one, screen both, and pick the winner. The extra cloning is trivial compared with re-screening if T7 fails on a difficult target.

Cost component tac promoter T7 promoter
Plasmid construction / cloning$100-300 (synthesis)$100-300 (synthesis)
IPTG per 10 L batch~$5 (0.5 mM)~$5 (0.5 mM)
Host strain (BL21 derivatives)$200-400 / glycerol vial$200-400 / glycerol vial
Licensing for commercial useNo restrictions on tac itselfpET license required (Novagen / MilliporeSigma)

Vendor landscape

The major commercial vector families and their promoter base. Note that several vendors offer both tac/trc and T7 backbones. Pick the family, then pick the promoter.

tac and trc promoter vendors

T7 promoter vendors

Frequently asked questions

Is T7 stronger than tac?
Yes. T7 RNA polymerase transcribes roughly five times faster than E. coli RNA polymerase, so the T7lac promoter is the stronger system on raw transcription rate. tac is still a strong promoter (about five times stronger than lacUV5) but operates at the host RNAP ceiling. For maximum titer of a well-behaved cytoplasmic protein, T7 wins. For toxic, membrane, or disulfide-rich proteins, tac often delivers more usable soluble product.
Why is BL21(DE3) needed for T7 but not for tac?
The T7 promoter is a phage sequence that E. coli RNA polymerase does not recognise, so transcription requires T7 RNA polymerase. BL21(DE3) carries that gene integrated as the lambda DE3 lysogen under lacUV5 control. BL21 without (DE3) has no T7 RNAP, so a T7 plasmid will not express. tac uses the host RNA polymerase directly, so it runs in any K-12 or B-strain background, including plain BL21, MG1655, JM109, and Origami.
Which promoter is leakier, tac or T7?
Both leak. tac shows steady basal expression in lacI strains because E. coli RNAP can initiate at low rates even with LacI bound, and that leakiness rises in prolonged cultures. T7 in BL21(DE3) inherits leakiness from the lacUV5 promoter driving T7 RNAP, and any leaked polymerase amplifies because T7 RNAP is so fast. In practice T7 leakiness is more dangerous because a single escaped polymerase produces large bursts of product. pLysS or pLysE strains and T7 promoters bearing the lac operator (T7lac) suppress this.
When should I use tac instead of T7?
Pick tac when (1) the target protein is toxic to E. coli and even brief T7 leakage kills the culture, (2) the protein needs slower translation to fold correctly and avoid inclusion bodies, (3) you need a non-(DE3) host (Origami for disulfides, Rosetta for rare codons in a non-DE3 background, or a K-12 strain), (4) the target is a membrane protein and T7 overproduction saturates the membrane, or (5) you want tunable expression by titrating IPTG without hitting a polymerase bottleneck.
What is the difference between tac and trc?
tac and trc are sister hybrid promoters sharing the trp -35 box and a lac-derived -10 box. tac uses the lacUV5 -10 sequence and has a 16 bp spacer; trc uses the wild-type lac -10 sequence and has a 17 bp spacer (the consensus E. coli RNAP spacing). In practice the two are functionally equivalent, with trc often shown to be marginally stronger and slightly less leaky. Both are IPTG-inducible, both require lacI or lacIq in the host, and either is a fine substrate when a tac vector is recommended.
Does plasmid copy number affect the tac vs T7 choice?
Yes, and the interaction is non-obvious. A 2021 Frontiers in Microbiology study found that pairing a strong promoter with a high copy number plasmid causes metabolic mismatch and reduces product yield. With T7 on a high copy number plasmid like pET (pBR322 origin, 15-20 copies), the resource drain on transcription/translation often beats yield down. tac on a low copy origin like p15A delivered the highest YFP titer in that study (53 mg/L), three-fold higher than T7lac on the same backbone.
Does tac work in BL21(DE3)?
Yes. tac is read by host RNAP and ignores the T7 RNAP that DE3 brings, so it runs fine in BL21(DE3). Many labs use a single host (BL21(DE3) or BL21(DE3) pLysS) for both T7 and tac plasmids to keep growth phenotype consistent across constructs. The only catch is that BL21(DE3) has chromosomal lacI under wild-type control, not lacIq, so basal repression of tac in BL21(DE3) is weaker than in JM109 or XL1-Blue. If basal expression is a problem, use a lacIq host or co-transform with a lacIq cassette.
What IPTG concentration should I use with tac vs T7?
For tac, 0.1-1.0 mM IPTG covers the working range; tac expression scales smoothly with IPTG dose over several orders of magnitude, so titrating between 0.025 and 0.5 mM is the standard tactic to tune soluble yield. For T7 in BL21(DE3), 0.1-0.5 mM is typical but the response is steeper because T7 RNAP saturates the ribosome pool quickly. Many groups now use 0.025-0.1 mM at induction OD600 of 0.6-0.8, then drop the temperature to 18-25 C for slow expression. The IPTG stock calculator linked below handles the dilution arithmetic.

Resources and references